Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radspherin in Platinum Sensitive Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma
NCT03732768Phase 1Completed
- Sponsor
- Oncoinvent ASA
- Start
- Jun 2020
- Primary completion
- Sep 2025
- Modality
- Nanoparticles
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of Radspherin in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal carcinoma (PPC) and 1 more, sponsored by Oncoinvent ASA. Primary endpoints: Dose Limiting Toxicities at 24 months and Maximum Tolerated Dose at 21 days. Started Jun 2020; status: completed.
02
Drugs
Radspherin
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal carcinoma (PPC)peritoneal carcinomatosis (PC)
Beyond the preview
Go deeper on NCT03732768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03732768.